Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H21N5O3S |
| Molecular Weight | 447.51 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)N=C(CNC(=O)C2=C(C=NC(=C2)C3=CC(C)=CN=C3)C4=NC=CS4)C=C1
InChI
InChIKey=VSOUDUXMPUHJEU-UHFFFAOYSA-N
InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)
| Molecular Formula | C23H21N5O3S |
| Molecular Weight | 447.51 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25248679/ |
MK-3697 plasma | Homo sapiens population: age: ADULT sex: food status: |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:27:55 GMT 2025
by
admin
on
Wed Apr 02 11:27:55 GMT 2025
|
| Record UNII |
M8238285OA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MK-3697
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | MedKoo CAT NO: 510214, CAS NO: 1224846-01-8Description: MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK-3697 is also the third insomnia drug, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. (Last updated: 8/6/2015). | ||
|
46190695
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | |||
|
M8238285OA
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY | |||
|
1224846-01-8
Created by
admin on Wed Apr 02 11:27:55 GMT 2025 , Edited by admin on Wed Apr 02 11:27:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
Ki
|
||
|
TARGET -> INHIBITOR |
BINDING
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Additional profiling established that compound 24 was moderately bound to plasma proteins with 84% (rat), 83% (dog), and 96% (human) binding across species and a log D of 1.9. The compound was highly permeable (Papp = 33 106 cm s1), and, while it was a substrate for P-glycoprotein (Pgp) efflux23 in mouse and rat with efflux ratios of 5.7 and 4.9, the compound demonstrated less Pgp susceptibility in human with a ratio of 2.9. Compound 24 was not a potent reversible inhibitor of CYP3A4, CYP2C9, or CYP2D6 (IC50s = 17, >50, >50 .MU.M), and it was not a potent activator of PXR with an EC50 of greater than 30 .MU.M and 16% activation compared to rifampicin control at 30 .MU.M. Off-target profiling of 2-SORA 24 showed no activities less than 10 .MU.M in a panel of 165 assays encompassing a range of targets including GPCRs, enzymes, and ion channels. Pharmacokinetic profiling of 2-SORA 24 revealed the compound had moderate clearance in rat and low clearance in dog with half-lives in an acceptable range for once-nightly treatment of insomnia. These data supported the selection of compound 24 as a preclinical candidate subsequently known as MK-3697.
|
